These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 37728835)
21. Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study). Abrisqueta P; Loscertales J; Terol MJ; Ramírez Payer Á; Ortiz M; Pérez I; Cuellar-García C; Fernández de la Mata M; Rodríguez A; Lario A; Delgado J; Godoy A; Arguiñano Pérez JM; Berruezo MJ; Oliveira A; Hernández-Rivas JÁ; García Malo MD; Medina Á; García Martin P; Osorio S; Baltasar P; Fernández-Zarzoso M; Marco F; Vidal Manceñido MJ; Smucler Simonovich A; López Rubio M; Jarque I; Suarez A; Fernández Álvarez R; Lancharro Anchel A; Ríos E; Losada Castillo MDC; Pérez Persona E; García Muñoz R; Ramos R; Yáñez L; Bello JL; Loriente C; Acha D; Villanueva M Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e985-e999. PubMed ID: 34511320 [TBL] [Abstract][Full Text] [Related]
22. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309 [TBL] [Abstract][Full Text] [Related]
23. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre. Uminski K; Brown K; Bucher O; Hibbert I; Dhaliwal DH; Johnston JB; Geirnaert M; Dawe DE; Banerji V Curr Oncol; 2019 Oct; 26(5):e610-e617. PubMed ID: 31708654 [TBL] [Abstract][Full Text] [Related]
24. The Real-World Experience With Single Agent Ibrutinib in Relapsed/Refractory CLL. Akpinar S; Dogu MH; Celik S; Ekinci O; Hindilerden IY; Dal MS; Davulcu EA; Tekinalp A; Hindilerden F; Ozcan BG; Hacibekiroglu T; Erkurt MA; Bagci M; Namdaroglu S; Korkmaz G; Bilgir O; Cagliyan GA; Ozturk HBA; Serin I; Tiryaki TO; Ozatli D; Korkmaz S; Ulas T; Eser B; Turgut B; Altuntas F Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):169-173. PubMed ID: 34629286 [TBL] [Abstract][Full Text] [Related]
25. Ibrutinib for treatment of chronic lymphocytic leukemia. Vela CM; McBride A; Jaglowski SM; Andritsos LA Am J Health Syst Pharm; 2016 Mar; 73(6):367-75. PubMed ID: 26953281 [TBL] [Abstract][Full Text] [Related]
26. Overall survival of patients with CLL treated with ibrutinib in the first line compared to second-line ibrutinib after chemotherapy/chemoimmunotherapy. Robak T; Doubek M; Ferrant E; Diels J; Andersone L; Wilbertz S; Healy NC; Neumayr L; van Sanden S Curr Med Res Opin; 2024 Aug; 40(8):1369-1378. PubMed ID: 38885086 [TBL] [Abstract][Full Text] [Related]
27. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients. Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705 [TBL] [Abstract][Full Text] [Related]
28. Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study. Mauro FR; Scalzulli PR; Scarfò L; Minoia C; Murru R; Sportoletti P; Frigeri F; Albano F; Di Renzo N; Sanna A; Laurenti L; Massaia M; Cassin R; Coscia M; Patti C; Pennese E; Tafuri A; Chiarenza A; Galieni P; Perbellini O; Selleri C; Califano C; Ferrara F; Cuneo A; Murineddu M; Palumbo G; Scortechini I; Tedeschi A; Trentin L; Varettoni M; Pane F; Liberati AM; Merli F; Morello L; Musuraca G; Tani M; Ibatici A; Regazzoni G; Di Candia M; Palma M; Arienti D; Molica S Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539561 [TBL] [Abstract][Full Text] [Related]
29. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Plosker GL; Figgitt DP Drugs; 2003; 63(8):803-43. PubMed ID: 12662126 [TBL] [Abstract][Full Text] [Related]
30. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. Mato AR; Roeker LE; Allan JN; Pagel JM; Brander DM; Hill BT; Cheson BD; Furman RR; Lamanna N; Tam CS; Handunnetti S; Jacobs R; Lansigan F; Bhavsar E; Barr PM; Shadman M; Skarbnik AP; Goy A; Beach DF; Svoboda J; Pu JJ; Sehgal AR; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Rhodes J; Ujjani CS; Nabhan C Am J Hematol; 2018 Nov; 93(11):1394-1401. PubMed ID: 30132965 [TBL] [Abstract][Full Text] [Related]
32. Real-World Treatment Patterns and Outcomes by Line of Therapy and Race in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated in the United States: Results From the Final Analysis of the Prospective, Observational, informCLL Registry. Ghosh N; Sharman JP; Gutierrez M; Khan W; Qureshi ZP; Raz A; Girardi V; Krigsfeld GS; Barrientos JC Clin Lymphoma Myeloma Leuk; 2024 Sep; 24(9):e301-e313. PubMed ID: 38845276 [TBL] [Abstract][Full Text] [Related]
33. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. O'Brien S; Furman RR; Coutre S; Flinn IW; Burger JA; Blum K; Sharman J; Wierda W; Jones J; Zhao W; Heerema NA; Johnson AJ; Luan Y; James DF; Chu AD; Byrd JC Blood; 2018 Apr; 131(17):1910-1919. PubMed ID: 29437592 [TBL] [Abstract][Full Text] [Related]
34. Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. O'Brien SM; Byrd JC; Hillmen P; Coutre S; Brown JR; Barr PM; Barrientos JC; Devereux S; Robak T; Reddy NM; Kipps TJ; Tedeschi A; Cymbalista F; Ghia P; Chang S; Ninomoto J; James DF; Burger JA Am J Hematol; 2019 May; 94(5):554-562. PubMed ID: 30767298 [TBL] [Abstract][Full Text] [Related]
35. Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis. Nunes RAB; Avezum Á; de Oliveira Marques M; Baiocchi OCCG; Bachour P Ann Hematol; 2024 Nov; 103(11):4613-4620. PubMed ID: 39153144 [TBL] [Abstract][Full Text] [Related]
36. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088 [TBL] [Abstract][Full Text] [Related]
38. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Rogers KA; Thompson PA; Allan JN; Coleman M; Sharman JP; Cheson BD; Jones D; Izumi R; Frigault MM; Quah C; Raman RK; Patel P; Wang MH; Kipps TJ Haematologica; 2021 Sep; 106(9):2364-2373. PubMed ID: 33730844 [TBL] [Abstract][Full Text] [Related]
39. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study. Shadman M; Flinn IW; Levy MY; Porter RF; Burke JM; Zafar SF; Misleh J; Kingsley EC; Yimer HA; Freeman B; Rao SS; Chaudhry A; Tumula PK; Gandhi MD; Manda S; Chen DY; By K; Xu L; Liu Y; Crescenzo R; Idoine A; Zhang X; Cohen A; Huang J; Sharman JP Lancet Haematol; 2023 Jan; 10(1):e35-e45. PubMed ID: 36400069 [TBL] [Abstract][Full Text] [Related]
40. A real-world study to assess the association of cardiovascular adverse events (CVAEs) with ibrutinib as first-line (1L) treatment for patients with chronic lymphocytic leukaemia (CLL) in the United States. Mato A; Tang B; Azmi S; Yang K; Han Y; Zhang X; Roeker L; Wallis N; Stern JC; Hedrick E; Huang J; Sharman JP EJHaem; 2023 Feb; 4(1):135-144. PubMed ID: 36819172 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]